Gaurav Kumar

Dr. Gaurav Kumar

TSET Health Promotion Research Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2022 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
Gaurav KumarGaurav Kumar
Gaurav Kumar
PCPriyanka Chaudhary
Priyanka Chaudhary
AQAiden Quinn
Aiden Quinn
DSDejun Su
Dejun Su
Barriers to clinical trial enrollment have been the subject of extensive research; however, the rate of clinical trial participation has not improved significantly over time. Studies often emphasize patient-related barriers, but institutional and organizational barriers in the health care system may have a more substantial impact on clinical trial participation. To qualitatively identify perceived barriers to clinical trial participation based on perspectives from healthcare providers. Qualitative research design with a phenomenological approach was used. A purposive sample of 18 healthcare providers participated in an in-depth focus group session. Participants were involved in cancer care and clinical research from a large hospital in the United States Midwest region. Data were transcribed, coded, and systematically analyzed through thematic content analysis. The data revealed four levels of barriers to clinical trial enrollment, with emergent themes within each level: patient (beliefs or trust, distance to trial sites, health insurance coverage, language, and immigration status), provider (limited awareness of trial, time constraint, and non-cooperation from colleagues), clinical (eligibility criteria and clinical design), and institutional (policy and limited logistic support). Healthcare providers face complex, multifaceted, and interrelated barriers to clinical trial enrollment. To overcome these barriers, health care organizations need to commit more human and financial resources, break down boundaries for more efficient inter-departmental cooperation, develop more coordinated efforts in promoting trial awareness and participation, and remove unnecessary regulatory barriers.

1 April 2020 in Asia-Pacific Journal of Oncology Nursing
Verified
Journal Article
Open access
ABAnn M Berger
Ann M Berger
Gaurav KumarGaurav Kumar
Gaurav Kumar
TLTricia D LeVan
Tricia D LeVan
JMJane L Meza
Jane L Meza
Asia Pac J Oncol Nurs, Official publication of Asian Oncology Nursing Society

20 June 2022 in Journal of Social Service Research
Verified
Journal Article
Closed access
DTDrissa Makan Toure
Drissa Makan Toure
Gaurav KumarGaurav Kumar
Gaurav Kumar
CWCady Walker
Cady Walker
JTJack E. Turman
Jack E. Turman
DSDejun Su
Dejun Su
The Centers for Disease Control and Prevention approximates that 1 in 5 children experience a mental or behavioral health disorder. Pediatric mental healthcare service access cannot be improved without strong coordination between educational settings, social service providers for children, and adequate policy support. Addressing this critical child development issue is dependent on us understanding the barriers to mental healthcare access faced by pediatric populations. This qualitative study explored barriers to pediatric mental healthcare access based on in-depth interviews with 53 key informants representing childcare settings, K-12 schools, foster care settings, and evidence-based home visitation programs. Semi-structured interviews with participants identified barrier-related themes and subthemes. The themes reflect a series of hurdles related to pediatric mental healthcare access including, lack of preparedness/training for pediatric mental health screening and management, limited resources, lack of policy support, transportation, and family issues that have hindered mental health support for children. The findings highlight the compounding barriers to pediatric mental healthcare services and point to opportunities for improving pediatric mental health using a holistic approach. Future research should focus on designing and implementing community and organization-based strategies to break down these barriers for families to optimize their children’s mental health and wellness.

15 September 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Gaurav KumarGaurav Kumar
Gaurav Kumar
JKJungyoon Kim
Jungyoon Kim
PFParaskevi A. Farazi
Paraskevi A. Farazi
HWHongmei Wang
Hongmei Wang
DSDejun Su
Dejun Su
Background: Cancer clinical trials (CCTs) are essential for cancer care, yet the evidence is scarce when it comes to racial disparities in CCT participation among cancer survivors in the Midwest. This study aimed to 1) assess disparities in the awareness of and willingness to participate in CCTs between African American and White cancer survivors; and 2) compare perceptions about CCTs between the two racial groups. Methods: The study was based on cross-sectional data from the survey “Minority Patient Participation in Cancer Clinical Trials” that collected information from 147 Black and White cancer survivors from Nebraska between 2015 and 2016. Chi-square tests and logistic regressions were used to assess differences between Black and White cancer survivors regarding their awareness, willingness, and perceptions associated with CCT participation. Results: After adjusting for the effects of socio-demographic, health status, and psychosocial variables, Black cancer survivors were much less likely than White cancer survivors to be aware of CCTs (AOR 0.26; CI 0.08–0.81), to express willingness to participate in CCTs (AOR 0.03; CI 0.01, 0.32) and to actually participate in CCTs (AOR 0.13; CI 0.04–0.38). Black cancer survivors reported a lower level of trust in physicians and were less likely than White cancer survivors to believe that CCTs make a significant contribution to science. Conclusions: Relative to White cancer survivors, Black cancer survivors had much lower awareness of and willingness to participate in CCTs. Part of these differences might be related to the differential perception of CCTs, psychosocial factors, and trust in physicians between the two groups.

17 August 2015 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
PDF file
SCShaunna L. Clark
Shaunna L. Clark
JMJoseph L. McClay
Joseph L. McClay
DADaniel E. Adkins
Daniel E. Adkins
KAKarolina A. Aberg
Karolina A. Aberg
Gaurav KumarGaurav Kumar
Gaurav Kumar
EOEdwin J. van Den Oord
Edwin J. van Den Oord
Genome-wide association study meta-analyses have robustly implicated three loci that affect susceptibility for smoking: CHRNA5\CHRNA3\CHRNB4 , CHRNB3\CHRNA6 and EGLN2\CYP2A6 . Functional follow-up studies of these loci are needed to provide insight into biological mechanisms. However, these efforts have been hampered by a lack of knowledge about the specific causal variant(s) involved. In this study, we prioritized variants in terms of the likelihood they account for the reported associations. We employed targeted capture of the CHRNA5\CHRNA3\CHRNB4 , CHRNB3\CHRNA6 , and EGLN2\CYP2A6 loci and flanking regions followed by next-generation deep sequencing (mean coverage 78×) to capture genomic variation in 363 individuals. We performed single locus tests to determine if any single variant accounts for the association, and examined if sets of (rare) variants that overlapped with biologically meaningful annotations account for the associations. In total, we investigated 963 variants, of which 71.1% were rare (minor allele frequency < 0.01), 6.02% were insertion/deletions, and 51.7% were catalogued in dbSNP141. The single variant results showed that no variant fully accounts for the association in any region. In the variant set results, CHRNB4 accounts for most of the signal with significant sets consisting of directly damaging variants. CHRNA6 explains most of the signal in the CHRNB3\CHRNA6 locus with significant sets indicating a regulatory role for CHRNA6 . Significant sets in CYP2A6 involved directly damaging variants while the significant variant sets suggested a regulatory role for EGLN2 . We found that multiple variants implicating multiple processes explain the signal. Some variants can be prioritized for functional follow-up.

1 July 2019 in Journal of Circadian Rhythms
Verified
Journal Article
Open access
PDF file
TLTricia D. LeVan
Tricia D. LeVan
PXPeng Xiao
Peng Xiao
Gaurav KumarGaurav Kumar
Gaurav Kumar
KKKevin Kupzyk
Kevin Kupzyk
FQFang Qiu
Fang Qiu
ABAnn M. Berger
Ann M. Berger
Women diagnosed with breast cancer (BC) are at increased risk of sleep deficiency. Approximately 30-60% of these women report poor sleep during and following surgery, chemotherapy, radiation therapy, and anti-estrogen therapy. The purpose of this study was to examine the relationship between genetic variation in circadian rhythm genes and self-reported sleep quality in women with BC. This cross-sectional study recruited women with a first diagnosis of breast cancer at five sites in Nebraska and South Dakota. Sixty women were included in the study. Twenty-six circadian genes were selected for exome sequencing using the Nextera Rapid Capture Expanded Exome kit. 414 variants had a minor allele frequency of ≥5% and were included in the exploratory analysis. The association between Pittsburgh Sleep Quality Index (PSQI) score and genetic variants was determined by two-sample t-test or ANOVA. Twenty-five variants were associated with the PSQI score at p < 0.10, of which 19 were significant at p<0.05, although the associations did not reach statistical significance after adjustment for multiple comparisons. Variants associated with PSQI were from genes CSNK1D & E, SKP1, BHLHE40 & 41, NPAS2, ARNTL, MYRIP, KLHL30, TIMELESS, FBXL3, CUL1, PER1&2, RORB. Two genetic variants were synonymous or missense variants in the BHLHE40 and TIMELESS genes, respectively. These exploratory results demonstrate an association of genetic variants in circadian rhythm pathways with self-reported sleep in women with BC. Testing this association is warranted in a larger replication population.